Qiming U.S. Ventures Management, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 13, 2024), Qiming U.S. Ventures Management, LLC reported 6 stock positions worth $52.6 million. Its top holding was Jasper Therapeutics (JSPR) at 40.1% of the portfolio, followed by Korro Bio (KRRO, 23.7%) and Tourmaline Bio (TRML, 18.1%). Its holdings were unchanged from Q1 2024.
- Most Recent 13F
- Q3 2025
- Location
- BELLEVUE, WA
- CIK
- 0001909617
- Portfolio Value
- $52.6M (Q2 2024)
- SEC Filing
- 0001104659-24-088978 ↗ filed Aug 13, 2024
Holdings Value
Holdings 6 stocks · $52.6M
| JSPR Jasper Therapeutics Inc. | 40.07% | 928,964 | $21.1M | No change |
| KRRO Korro Bio Inc. | 23.69% | 368,085 | $12.5M | No change |
| TRML Tourmaline Bio Inc. | 18.13% | 741,691 | $9.5M | No change |
| HLVX Hillevax Inc. | 15.36% | 558,923 | $8.1M | No change |
| VTYX Ventyx Biosciences Inc. | 1.81% | 412,225 | $952K | No change |
| KEZAR LIFE SCIENCES INC | 0.94% | 828,711 | $497K | No change |
Portfolio Sells Q1 2024 → Q2 2024
| None this quarter. | |||
Portfolio Buys Q1 2024 → Q2 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q3 2025 | 4 | $55.6M | TRML, KRRO, JSPR, KZR |
| Q2 2025 | 6 | $23.6M | TRML, JSPR, KRRO, VTYX, HLVX |
| Q1 2025 | 6 | $23.1M | TRML, KRRO, JSPR, HLVX, VTYX |
| Q4 2024 | 6 | $51.1M | JSPR, TRML, KRRO, VTYX, HLVX |
| Q3 2024 | 6 | $51.4M | TRML, JSPR, KRRO, HLVX, VTYX |
| Q2 2024 | 6 | $52.6M | JSPR, KRRO, TRML, HLVX, VTYX |
| Q1 2024 | 6 | $89.7M | KRRO, JSPR, TRML, HLVX, VTYX |